Women of Child-Bearing Potential: There is no information available on the effects of rivastigmine in women of child-bearing potential.
Pregnancy: In animal studies, rivastigmine was not teratogenic. However, the safety of Exelon in human pregnancy has not been established, and it should only be given to pregnant women if the potential benefit outweighs the potential risk for the foetus.
Breast-feeding: In lactating animals, rivastigmine and/or metabolites were excreted in breast milk. It is not known if Exelon is excreted into human milk, and patients on Exelon should therefore not breast-feed.
Fertility: There is no information available on the effects of rivastigmine on human fertility.